Guo Jun et al. reported that genetic aberrations in the cyclin-dependent kinase (CDK)4 pathway occur in 82% of patients with acral melanoma, showed CDK4 gain (39.5%) and CCND1 gain (26.7%). This evidence concerns the gene CDK4 and acral lentiginous melanoma.